An observational study in Progressive Supranuclear Palsy, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-08.
Sponsored by Assistance Publique Hopitaux De Marseille · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Supranuclear Palsy, Progressive with a site in France — 6 open to participants now, 6 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · France.
Among the 22 studies in Supranuclear Palsy, Progressive with a site in France, this one is the only one that started in 2019, is one of 6 observational ones, and was the 14th registered.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
Browse Supranuclear Palsy, Progressive studies →6 of the 22 studies in Supranuclear Palsy, Progressive with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Australia and 9 more countries
Ages 41–81
University Hospital, Bordeaux · Sites in France
Ages 18+
SYSNAV · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 40–89
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 40–80 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 66 observational studies indexed under Supranuclear Palsy, Progressive.
Median enrollment 130 across the 16 interventional studies, 150 across the 6 observational. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 3 studies filed under Supranuclear Palsy, Progressive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Supranuclear Palsy, Progressive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group.
PSP is characterised by the association of a non-doparesponsive parkinsonian syndrome with axial signs. The latter predominantly manifest as a psycho-motor slowness, an apathy and frontal executive deficits. Swallowing impairments may additionally provoke life-threatening situations. Today the treatment is mostly symptomatic as no cure is available. Given the limited treatment options and its clinical characteristics, PSP deeply impact on the patients' quality of life (QoL) as well as on their caregivers'. Nevertheless a limited number of studies have focused on these aspects. A better understaning of the factors determining both patient and cargiver QoL may help optimising their care.
the principal objective of this study is to identify the determinants of PSP patients' QoL.
The secondary objectives are : i) to identify the determinants (medical, behavioural, socio-economic, environmental ...) of PSP patients' caregivers' QoL and burden ; ii) to validate in French language the QoL scale specific for PSP available in English (PSP-QoL).
This is a multidisciplinary transversal study. 2 subject groups will be included : i) PSP patients ; ii) caregiver of PSP patients (designated by the patient as being the person closest to them), Data collected : i) from the patient : socio-demographic, social and professionnal environment, clinical (disease duration and severity, neuropsychological evaluation), therapeutic, mood, anxiety, coping, body image, QoL ; ii) from the caregiver: socio-demographic, social and professionnal environment, connection with the patient, data relative to their own health, mood, anxiety, coping, QoL, burden.
Progress : patient information, designation of a caregiver, consent collection, collection of data Statistical analysis : To address the principal objective 'patient' QoL scores will be confronted to the other collected variables (Student's t-test, correlation coefficient). The results will be adjusted to the confounding factors using multivariate analyses.
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group. It represents 5 to 10% of all parkinsonian syndromes and affects 3000 to 10000 persons in France.
PSP is characterised by the association of a non-doparesponsive parkinsonian syndrome with axial signs such as early gait instability and falls, oculomotor signs such as a vertical gaze limitation and both cognitive and behavioural disturbances. The latter predominantly manifest as a psycho-motor slowness, an apathy and frontal executive deficits. Swallowing impairments may additionally provoke life-threatening situations. Today the treatment is mostly symptomatic as no cure is available. Given the limited treatment options and its clinical characteristics, PSP deeply impact on the patients' quality of life (QoL) as well as on their caregivers'. Nevertheless a limited number of studies have focused on these aspects. A better understaning of the factors determining both patient and cargiver QoL may help optimising their care.
Objectives : the principal objective of this study is to identify the determinants (motor, behavioural, socio-economic, environemental...) of PSP patients' QoL.
The secondary objectives are : i) to identify the determinants (medical, behavioural, socio-economic, environmental ...) of PSP patients' caregivers' QoL and burden ; ii) to validate in French language the QoL scale specific for PSP available in English (PSP-QoL).
Methods : This is a multidisciplinary transversal study. Population : 2 subject groups will be included : i) PSP patients ; ii) caregiver of PSP patients (designated by the patient as being the person closest to them), Data collected : i) from the patient : socio-demographic, social and professionnal environment, clinical (disease duration and severity, neuropsychological evaluation), therapeutic, mood, anxiety, coping, body image, QoL ; ii) from the caregiver: socio-demographic, social and professionnal environment, connection with the patient, data relative to their own health, mood, anxiety, coping, QoL, burden.
Progress : patient information, designation of a caregiver, consent collection, collection of data Statistical analysis : To address the principal objective 'patient' QoL scores will be confronted to the other collected variables (Student's t-test, correlation coefficient). The results will be adjusted to the confounding factors using multivariate analyses. To address the secondary objective, 'caregiver' QoL and burden scores will be confronted to the other collected variables through the same procedure. The transcultural validation of the PSP-QoL scale will be obtained using standard methodology: forward-backward method, acceptability test, study of metric properties.
Expected results and impact: This work will help understanding the social handicap in PSP and may lead to new therapeutic strategies.
Relevance of the project: No data on PSP-related QoL or caregiver burden are available in France In addition, the factors determining these aspects of the disease are poorly understood. The motor handicap obviously reduces patients' QoL and increases the caregivers' burden. However the impact of the cognitive and behavioural disturbances and particularly the reduction of social interactions on the QoL of patients and caregiver burden have been less studied.
PSP patients with their caregivers
Inclusion Criteria (patients)
Female or male, age ≥ 40 years at the time of onset of symptoms
Exclusion Criteria (patients)
Inclusion Criteria (caregivers)
Exclusion Criteria (caregivers)
patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group
Other: PSP-QoL
the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group
Other: PSP-QoL
PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP. PSP-QoL consists of 28 items scored on a 3- or 5-point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more-severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings.
score of PSP-QoL questionnaire
the score obtained by group will be compare Progressive Supranuclear Palsy (PSP) Quality of Life questionnaire by Schrag and collaborators in 2006. 14 items, 5 degree from no problem, slight problem, moderate problem, marked problem to extreme problem (1 to 5 points) minimum score:14 maximum score : 70
Time frame: 1 hour
Started Jul 2019 (actual). Primary completion is estimated for Jul 2026, 84 months after the start.
Of 37 observational studies under Supranuclear Palsy, Progressive, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 54. This study's planned 84 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supranuclear Palsy, Progressive →
Assistance Publique Hopitaux De Marseille →